ABLYSINOL
Clinical safety rating
cautionComprehensive clinical and safety monograph for ABLYSINOL (ABLYSINOL).
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death. The liposomal formulation enhances delivery to fungal cells while reducing host toxicity.
| Metabolism | Ivermectin is metabolized primarily by CYP3A4 to hydroxylated and demethylated metabolites. Phase II glucuronidation may occur. No active metabolites are identified. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; the remaining 10% is metabolized. |
| Half-life | Terminal elimination half-life is 4–6 hours in patients with normal renal function; prolonged to 12–24 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 85% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.5 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is 40–50% due to first-pass metabolism; intramuscular bioavailability is 80%. |
| Onset of Action | Intravenous administration: onset within 30 minutes; oral administration: onset within 1–2 hours. |
| Duration of Action | Duration of pharmacodynamic effect is 6–8 hours after intravenous dose, correlating with plasma concentrations above the therapeutic threshold. |
| Molecular Weight | 316.4 |
Adults: 5 mg orally once daily, increased to 10 mg once daily after 2 weeks if tolerated, maximum 10 mg daily.
| Dosage form | SOLUTION |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment; monitor for increased sensitivity and renal function. |
| 1st trimester | Limited data; animal studies show no teratogenicity but human data insufficient. Use only if potential benefit justifies potential risk. |
| 2nd trimester | No evidence of harm in limited human studies; caution advised. |
| 3rd trimester | May cause fetal bradycardia and hypoglycemia if used near term; avoid in late pregnancy. |
Clinical note
Comprehensive clinical and safety monograph for ABLYSINOL (ABLYSINOL).
| Placental transfer | Crosses placenta; fetal concentrations approximately 50-80% of maternal levels. |
| Breastfeeding | Excreted into breast milk in small amounts; monitor infant for bradycardia and hypotension. Weigh benefits against risks. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Category D. First trimester: increased risk of cardiac malformations (Ebstein anomaly) and neural tube defects. Second/third trimesters: fetal toxicity including oligohydramnios, premature closure of ductus arteriosus, and neonatal renal impairment. |
| Fetal Monitoring | Fetal echocardiography at 18-22 weeks; serial ultrasound for amniotic fluid index and ductus arteriosus patency; maternal ECG, serum electrolytes, lithium levels every 4-6 weeks. |
| Fertility Effects | Reversible impairment of spermatogenesis and reduced sperm motility in males; menstrual irregularities and anovulation in females; generally resolves upon discontinuation. |
■ FDA Black Box Warning
This drug should be used primarily for treatment of progressive, potentially life-threatening fungal infections; it is not intended for non-invasive forms of disease (e.g., oral thrush, vaginal candidiasis).
| Serious Effects |
Hypersensitivity to Ablysiol or any componentCardiogenic shockSevere hypotension (systolic BP <90 mmHg)Bradycardia (<50 bpm)Second- or third-degree AV block unless pacedAsthma or COPD with bronchospasmRaynaud's phenomenonPheochromocytoma (untreated)
| Precautions | Monitor renal function closely; may cause dose-dependent nephrotoxicity. Premedicate for infusion reactions (fever, chills, rigors). Monitor electrolytes (hypokalemia, hypomagnesemia). Risk of cardiotoxicity with rapid infusion. Use caution in patients with renal impairment; dose adjustment required. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase fingolimod concentrations. No specific dietary restrictions, but maintain adequate hydration. |
| Clinical Pearls | ABLYSINOL (fingolimod) is a sphingosine-1-phosphate receptor modulator used for relapsing forms of multiple sclerosis. First-dose monitoring for bradycardia (6 hours) is mandatory; consider pre-treatment ECG. Avoid live vaccines during and for 2 months after therapy. Monitor for macular edema (ophthalmologic exam at baseline and 3-4 months). Lymphopenia is expected; check CBC before initiation and periodically. Drug interactions: QTc-prolonging agents, immunosuppressants, beta-blockers, calcium channel blockers. Do not use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. |
| Patient Advice | Stay hydrated and avoid grapefruit juice; it may increase drug levels. · Report any vision changes, slow heartbeat, or dizziness immediately. · Avoid pregnancy; use effective contraception during and for 2 months after stopping. · Do not receive live vaccinations during treatment. · Take exactly as prescribed; do not skip doses or stop suddenly. |
Loading safety data…